Wave Life Sciences Ltd (NASDAQ:WVE)’s traded shares stood at 1.43 million during the last session, with the company’s beta value hitting -1.23. At the close of trading, the stock’s price was $13.67, to imply a decrease of -8.87% or -$1.33 in intraday trading. The WVE share’s 52-week high remains $16.74, putting it -22.46% down since that peak but still an impressive 74.4% since price per share fell to its 52-week low of $3.50. The company has a valuation of $2.08B, with an average of 1.3 million shares in intraday trading volume over the past 10 days and average of 1.74 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Wave Life Sciences Ltd (WVE), translating to a mean rating of 1.20. Of 3 analyst(s) looking at the stock, 0 analyst(s) give WVE a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Wave Life Sciences Ltd (NASDAQ:WVE) trade information
After registering a -8.87% downside in the last session, Wave Life Sciences Ltd (WVE) has traded red over the past five days. The 5-day price performance for the stock is -16.85%, and -6.43% over 30 days. With these gigs, the year-to-date price performance is 170.69%. Short interest in Wave Life Sciences Ltd (NASDAQ:WVE) saw shorts transact 6.82 million shares and set a 3.38 days time to cover.
The extremes give us $15 and $36 for target low and target high price respectively. As such, WVE has been trading -163.35% off suggested target high and -9.73% from its likely low.
Wave Life Sciences Ltd (WVE) estimates and forecasts
Looking at statistics comparing Wave Life Sciences Ltd share performance against respective industry, we note that the company has underperformed competitors. Wave Life Sciences Ltd (WVE) shares are 118.37% up over the last 6 months, with its year-to-date growth rate lower than industry average at -101.85% against 17.70%. Revenue is forecast to shrink -61.85% this quarter before falling -22.92% for the next one. The rating firms project that company’s revenue will shrink -53.97% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is 17.73M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 9.4M.Earnings reports from the last fiscal year show that sales brought in 29.06M and 12.54M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -38.98% before dropping -25.03% in the following quarter.
WVE Dividends
Wave Life Sciences Ltd has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Wave Life Sciences Ltd (NASDAQ:WVE)’s Major holders
Wave Life Sciences Ltd insiders hold 15.07% of total outstanding shares, with institutional holders owning 78.34% of the shares at 92.25% float percentage. In total, 78.34% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P.. As of 2024-06-30, the company held over 18.2 million shares (or 14.0527% of shares), all amounting to roughly $90.83 million.
The next major institution holding the largest number of shares is MAVERICK CAPITAL LTD with 7.67 million shares, or about 5.9211% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $38.27 million.
